Deals
Concordia Agrees to Buy Covis Health Assets for $1.2 Billion
This article is for subscribers only.
Concordia Healthcare Corp. agreed to buy almost all of the commercial assets of closely held Covis Pharma Sarl and Covis Injectables Sarl for $1.2 billion in cash to diversify sales and boost margins.
“This is obviously a landmark transaction for Concordia and it takes us into a whole other realm,” Concordia Chief Executive Officer Mark Thompson said Monday on a conference call.